Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2025
Serum 25-hydroxyvitamin D levels did not improve with N-Acetylcysteine administration or with abstinence in adults treated for alcohol use disorder: a secondary analysis of a randomized, double-blind, placebocontrolled clinical trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Piazza Fernanda Reginna Gramkow, Schuch Jaqueline Bohrer, Silvello Daiane, Gabiatti Mariana Papini, Kessler Felix Henrique Paim, von Diemen Lisia, Hansen Fernanda
Аннотация
OBJECTIVE: N-acetylcysteine is a medication known for its hepatoprotective properties and potential to reduce cravings and psychoactive substance use. Vitamin D is metabolized in the liver, and individuals with alcohol use disorder often have lower levels. This study assessed the effects of N-acetylcysteine administration on 25-hydroxyvitamin D (25[OH]D) in adults being treated for alcohol use disorder.
METHODS: This is a secondary analysis of a randomized, double-blind, placebo-controlled study with 47 male alcohol use disorder patients who received either N-acetylcysteine (600 mg twice daily, n=22) or placebo (n=25) for 8 weeks. Blood samples were analyzed to assess 25(OH)D levels, liver and renal functions, and glutathione metabolism. The effects of time, intervention, and their interaction on 25(OH)D level were evaluated using generalized estimating equations.
RESULTS: Upon hospitalization, 45% and 21.7% of the patients had 25(OH)D deficiency and insufficiency, respectively. After 8 weeks, 43.3% and 40% of the patients had 25(OH)D deficiency and insufficiency, respectively. Intervention (N-acetylcysteine vs. placebo) (p = 0.130), study time (p = 0.429), and their interaction (p = 0.834) showed no significant effect on 25(OH)D levels.
CONCLUSIONS: There is a high prevalence of 25(OH)D deficiency and insufficiency in alcohol use disorder patients. Levels of 25(OH)D did not improve spontaneously with abstinence, and N-acetylcysteine intervention did not significantly affect 25(OH)D concentrations.
METHODS: This is a secondary analysis of a randomized, double-blind, placebo-controlled study with 47 male alcohol use disorder patients who received either N-acetylcysteine (600 mg twice daily, n=22) or placebo (n=25) for 8 weeks. Blood samples were analyzed to assess 25(OH)D levels, liver and renal functions, and glutathione metabolism. The effects of time, intervention, and their interaction on 25(OH)D level were evaluated using generalized estimating equations.
RESULTS: Upon hospitalization, 45% and 21.7% of the patients had 25(OH)D deficiency and insufficiency, respectively. After 8 weeks, 43.3% and 40% of the patients had 25(OH)D deficiency and insufficiency, respectively. Intervention (N-acetylcysteine vs. placebo) (p = 0.130), study time (p = 0.429), and their interaction (p = 0.834) showed no significant effect on 25(OH)D levels.
CONCLUSIONS: There is a high prevalence of 25(OH)D deficiency and insufficiency in alcohol use disorder patients. Levels of 25(OH)D did not improve spontaneously with abstinence, and N-acetylcysteine intervention did not significantly affect 25(OH)D concentrations.